Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.

Can incorporating molecular testing improve the accuracy of newborn screening for congenital adrenal hyperplasia

Open access

Abstract

Context: Single-tier newborn screening (NBS) for congenital adrenal hyperplasia (CAH) using 17-hydroxyprogesterone (17OHP) measured by fluoroimmunoassay (FIA) in samples collected at 24 to 48 hours produces a high false-positive rate (FPR). Second-tier steroid testing can reduce the FPR and has been widely implemented. Objective: We investigated the accuracy of an alternative multitier CAH NBS protocol that incorporates molecular testing of the CYP21A2 gene and reduces the first-tier 17OHP cutoff to minimize missed cases. Methods: We create a Minnesota-specific CYP21A2 pathogenic variants panel; developed a rapid, high-throughput multiplex, allele-specific-primer-extension assay; and performed a 1-year retrospective analysis of Minnesota NBS results comparing metrics between a conventional steroid-based 2-tier protocol and a molecular-based multitier NBS protocol, applied post hoc. Results: CYP21A2 gene sequencing of 103 Minnesota families resulted in a Minnesota-specific panel of 21 pathogenic variants. The Centers for Disease Control and Prevention created a molecular assay with 100% accuracy and reproducibility. Two-tier steroid-based screening of 68 659 live births during 2015 resulted in 2 false negatives (FNs), 91 FPs, and 1 true positive (TP). A 3-tier protocol with a lower first-tier steroid cutoff, second-tier 21-variant CYP21A2 panel, and third-tier CYP21A2 sequencing would have resulted in 0 FNs, 52 FPs, and 3 TPs. Conclusion: Incorporation of molecular testing could improve the accuracy of CAH NBS, although some distinct challenges of molecular testing may need to be considered before implementation by NBS programs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgae297

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Long-range amplification-based method (LRAM) to detect A, the CYP21A2 gene; B, 30-kb deletion; and C, large gene conversion alleles. A, The CYP21A1P pseudogene and CYP21A2 gene are part of a 30-kb chromosomal duplication. B, Recombination between CYP21A1P and CYP21A2 deletes a 30-kb section of the repeat forming a fusion of the 5′ end of the pseudogene with the 3′ portion of CYP21A2. C, A unidirectional transfer of pseudogene sequence to CYP21A2 in a large-scale gene conversion results in a fusion of the 5′ end of CYP21A2 with the 3′ end of CYP21A1P.
Figure 1. Long-range amplification-based method (LRAM) to detect A, the CYP21A2 gene; B, 30-kb deletion; and C, large gene conversion alleles. A, The CYP21A1P pseudogene and CYP21A2 gene are part of a 30-kb chromosomal duplication. B, Recombination between CYP21A1P and CYP21A2 deletes a 30-kb section of the repeat forming a fusion of the 5′ end of the pseudogene with the 3′ portion of CYP21A2. C, A unidirectional transfer of pseudogene sequence to CYP21A2 in a large-scale gene conversion results in a fusion of the 5′ end of CYP21A2 with the 3′ end of CYP21A1P.CC BY · PubMed Central
Figure 2. Algorithm of molecular-based protocol for newborn screening for congenital adrenal hyperplasia (CAH). A, Molecular protocol—all second-tier CYP21A2 samples with one or more pathogenic variants sent to third-tier sequencing. If 2 or more pathogenic variants are confirmed, the newborn was referred to pediatric endocrinologist for serum 17-hydroxyprogesterone (17OHP) and/or adrenocorticotropin stimulation confirmation testing.
Figure 2. Algorithm of molecular-based protocol for newborn screening for congenital adrenal hyperplasia (CAH). A, Molecular protocol—all second-tier CYP21A2 samples with one or more pathogenic variants sent to third-tier sequencing. If 2 or more pathogenic variants are confirmed, the newborn was referred to pediatric endocrinologist for serum 17-hydroxyprogesterone (17OHP) and/or adrenocorticotropin stimulation confirmation testing.CC BY · PubMed Central
Figure 3. Algorithm of steroid-based protocol for newborn screening for congenital adrenal hyperplasia (CAH). *17-Hydroxyprogesterone (17OHP) value greater than or equal to 100 ng/mL and gestation age greater than 37 weeks are sent directly to confirmatory testing.
Figure 3. Algorithm of steroid-based protocol for newborn screening for congenital adrenal hyperplasia (CAH). *17-Hydroxyprogesterone (17OHP) value greater than or equal to 100 ng/mL and gestation age greater than 37 weeks are sent directly to confirmatory testing.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 9

Metadata

Authors
Sarafoglou, K., Gaviglio, A., Wolf, C., Lorentz, C. P., Lteif, A., Kyllo, J., Radloff, G., Detwiler, Z., Cuthbert, C. D., Hodges, J. S., Grosse, S. D., Greene, C. N., & Cordovado, S.
Affiliations
  • University of Minnesota (US)
  • Minnesota Department of Health (US)
  • Mayo Clinic (US)
  • Children’s Minnesota - St. Paul Hospital (US)
  • Centers for Disease Control and Prevention (US)
Corresponding author
Sarafoglou, Kyriakie
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2024-05-03
Volume
110
Issue
4
Pages
e1194-e1203
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W4396605079
Cited by
8
References
32
Citations by year
2026: 4 · 2025: 3 · 2024: 1
FWCI
1.09
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
March of Dimes (6-FY14-440)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
congenital adrenal hyperplasia, newborn screening, CYP21A2 gene, molecular testing, 17-hydroxyprogesterone, false positive rate
MeSH terms
Adrenal Hyperplasia, Congenital, False Positive Reactions, Female, Genetic Testing, Humans, Infant, Newborn, Male, Minnesota, Retrospective Studies, Steroid 21-Hydroxylase, Fluoroimmunoassay, Reproducibility of Results, Neonatal Screening, 17-alpha-Hydroxyprogesterone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Can incorporating molecular testing improve the accuracy of newborn screening for congenital adrenal hyperplasia. https://app.cochat.ai/papers/10.1210/clinem/dgae297
The paper
Sarafoglou, K., Gaviglio, A., Wolf, C., Lorentz, C. P., Lteif, A., Kyllo, J., Radloff, G., Detwiler, Z., Cuthbert, C. D., Hodges, J. S., Grosse, S. D., Greene, C. N., & Cordovado, S. (2025). Can incorporating molecular testing improve the accuracy of newborn screening for congenital adrenal hyperplasia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae297

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.